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The Role of Neutrophil 
Extracellular Traps (NETs) in the 
Pathogenesis and Complications 
of Malignant Diseases
Sheniz Yuzeir and Liana Gercheva
Abstract
It was recently proved that neutrophils and platelets are active participants 
in some inflammatory processes as well as a number of pathological conditions, 
including neoplastic diseases and thrombosis. It has been found that circulating 
neutrophils actively affect the mechanisms of tumour genesis, and along with 
platelets, act as independent regulators of different complications in infectious 
and malignant diseases. A few years ago, it was found that neutrophils have the 
ability to release extracellular traps (called neutrophil extracellular traps or NETs). 
Thus, neutrophils use both intracellular and extracellular mechanisms to limit 
inflammatory complications. Several recent studies confirmed that NETs increase 
considerably in malignant diseases, demonstrating that tumour-induced NETosis 
is a clinically significant process. It is recognised as an element of tumour biology, 
as it participates in tumour progression and angiogenesis. Neutrophils and the 
NETs released from them are stimulators of thrombotic processes in physiological 
and pathological conditions. Several reports demonstrate the connection between 
NETs and thrombosis. The presence of NETosis serves as a potential risk factor 
for thrombotic complications in malignant diseases. This chapter summarises the 
current knowledge of NETosis and the mechanisms that lead to the formation of 
NETs, including the role of circulating platelet–neutrophil complexes as regulators 
of tumour-induced NETosis in malignant diseases.
Keywords: NETosis, neutrophils, platelets, malignant diseases, infections
1. Introduction
One of the important causes of increased mortality in patients suffering from 
different inflammatory and neoplastic diseases is thrombosis of a large artery or 
vein. Recently, the attention of study groups has been drawn to the newly discov-
ered functions of neutrophils, which confirm their significant role in not only 
inflammatory processes but also a number of pathological conditions, including 
neoplastic diseases and thrombosis [1, 2].
Neutrophils, as inherent mediators of immune defence, play an important 
role in various inflammatory processes [1]. Studies of the content of neutrophil 
granules reveal that an abundance of enzymes and macromolecules have roles in 
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the different cellular interactions of granulocytes [3]. Enzyme-rich content reflects 
the active participation of neutrophils in the protective inflammatory response to 
bacteria, fungi and, to a lesser extent, other infections. These enzyme-mediated 
reactions are activated after membrane signalisation from the granulocyte plasma-
lemma, which possesses adhesive proteins, receptor molecules and ionic channels 
with pump mechanisms [4, 5]. Some receptor molecules have enzyme activity 
that inactivates cytokines and interleukins or activates intracellular processes for 
chemotactic movement of neutrophils through circulation from endothelial pores 
to tissues [6, 7]. Their ability to absorb pathogens and activate apoptosis through 
intracellular phagolysosomes is well known. After apoptosis was first described 
in 1972, several other mechanisms of cellular death were revealed, and decoding 
the paths leading to cellular death has remained a subject of discussion. In 2004, 
a group of scientists led by Brinkman [8] proved that stimulation of neutrophils 
with interleukin 8 (IL-8) or lipopolysaccharides (LPSs) causes liberation of 
chromatin in the extracellular space. Thus, these specific inflammatory cells release 
neutrophilic extracellular traps (NETs), which are formed mainly by decondensed 
nucleosomes and chromatin extracted from intracellular granules, such as neutro-
phil elastase and myeloperoxidase. So, it has been proven that neutrophils use both 
intracellular and extracellular mechanisms to confine infections.
The process of NET formation is called NETosis. This is characterised as a 
new process of cellular death that leads to chromatin decondensation, followed 
by cellular protein disintegration, lysis of the cytoplasm membrane and release 
of NETs [9]. The process of NETosis is dependent on enzyme peptidylarginine 
deaminase 4 (PAD4), which catalyses the transformation of histone-associated 
arginine residues into citrulline. It is mediated through the transformation of 
the α-amino group of arginine into a ketone group with subsequent chromatin 
decondensation [10–12].
The molecular mechanisms leading to NET formation remain unclear. According 
to recent data, the release of NETs in the extracellular space depends on two impor-
tant processes: generation of reactive oxygen species (ROS) and decondensation of 
chromatin. The production of ROS is realised by activating nicotinamide adenine 
dinucleotide phosphate, (NADPH) oxydase as well as by including additional signal 
paths that mediate different forms of NETosis. The activation of protein kinase C 
leads to the assembly of a NOX 2 complex in the phagosome membrane and subse-
quent electronic transport and formation of hydrogen peroxide (H2O2), which is a 
powerful inductor for the generation of NETs [9, 13].
The second process leading to the formation of NETs is decondensation of 
chromatin. Interestingly, the additional release of lipopolysaccharides demon-
strates that neutrophil elastase from azurophilic granules is the etiologic agent 
of this phenomenon. After neutrophil activation, the enzyme moves to the cel-
lular nucleus and decomposes histones, particularly histone 4, while the nuclear 
changes and decondensation of chromatin are both proportional to the level of 
histone 4 decomposition [14]. This implies that the other enzyme included in the 
process of NET formation is myeloperoxidase [15]. An important step in NET for-
mation is epigenetic modification of the histones, so-called histone citrullination 
through activation of the enzyme peptidyl-arginine deaminase (PAD4). Histone 
citrullination prevents histone methylation and further transcription, eventually 
resulting in chromatin decondensation [12, 16]. Releasing NET into the extracel-
lular space involves a series of interconnected processes. The first process occurs 
when the nuclear and granular membrane disintegrates and elastase enters the 
nucleus; the second process involves the hypercytrulinisation of histones; the third 
process includes decondensation in the cytoplasm; and the fourth process tran-
spires when the plasma membrane ruptures and nuclear material is extruded from 
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the cell in the outer space. Certain enzymes, such as peptidyl arginine deminase 
type IV (PAD4), neutrophil elastase (NE) and myeloperoxidase (MPO), play key 
roles in the chromatin decondensation process [17, 18]. Extracellular DNA, his-
tones and granular enzymes form a network of NETs that capture endogenous (e.g. 
platelets) and external (e.g. bacteria) particles. In addition, molecules are involved 
in the formation of HETs. Negatively charged DNA has been determined to act as 
the basis for NET and to interact with other NET components through a positive 
electrostatic charge. Although a number of studies have used PMA as an inducer of 
NET, the exact intracellular pathway that leads to the release of NET has yet to be 
determined [19, 20].
Most studies have concluded that an important autophagy process is activated in 
the formation of NETs. Autophagy is an anti-apoptotic mechanism that activates in 
response to cell stress. It occurs in order to regulate protein and organelle turnover, 
ensuring cell survival [21]. The protein kinase mammalian target of rapamycin 
(mTOR) negatively regulates autophagy, which is also involved in the formation 
of NET [22, 23]. Most studies have indicated that an important autophagy process 
is activated during the formation of NETs. Some intracellular signalling pathways, 
such as the PICK3 blocking autophagy, inhibit the release of NETS. It has been 
presumed that autophagy is critical to the release of NET in both infectious and 
non-infectious diseases, such as sepsis, familiar Mediterranean fever (FMF), gout 
and inflammatory-driven fibrosis. [24, 25].
The main components of NETs are DNA, histones and proteases, which have 
pro-coagulation properties. Histones have a marked cytotoxic effect on the vascular 
endothelium and can induce thrombosis [26]. Sulphurous proteases, such as neutro-
phil elastase, inactivate the tissue factor pathway inhibitor and lead to hypercoagu-
lation and fibrin deposition [27].
The critical role of neutrophils in the processes of tumour genesis has been 
emphasised in a number of publications. As inflammatory cells, they release dif-
ferent types of cytokines and chemokines that, through activation of intercellular 
interactions and modulation of the immune response, influence the tumour micro-
environment [28]. In addition, the proteases secreted by neutrophils have a specific 
role in regulation of the proliferation of tumour cells, tumour angiogenesis and the 
metastasis process. Different activating cytokines [IL-8, granulocyte colony-stimu-
lating factor (G-CSF) and tumour necrosis factor alpha], myeloperoxidase, neutro-
phil elastase and histone citrullination are included in the NET release process [21].
Some studies emphasise the critical role of G-CSF in tumour-induced NETosis. 
It is known that a major proportion of tumour cells produce G-CSF, which induces 
neutrophilia, a common finding in malignant diseases, which is usually related to 
poor prognosis. By releasing NETs, neutrophils provide a scaffold and stimulate the 
processes of platelet adhesion and aggregation. They are closely linked to tumour 
cells in vivo and in the tumour vasculature, but their role in tumour biology is still a 
subject of discussion.
Tumour-induced neutrophils have both pro- and anti-tumour potential. On the 
one hand, they secrete cytokines, generate thrombin and initiate positive feedback 
for stimulation of tumour growth, tumour invasion and maintenance of tumour 
angiogenesis. On the other hand, the anti-tumour potential of neutrophils is 
explained by their direct cytotoxic interaction with cancer cells, which stimulates 
the apoptotic decomposition of tumour cells due to their antibody-dependent 
cell-mediated cytotoxicity and favours their migration [29]. A number of studies 
have confirmed that tumours expressing high levels of G-CSF are powerful induc-
tors of NETosis [30]. Also, cytokine IL-8, which is frequently expressed by different 
tumour cells, is described as a NET-inducing factor and has recently been proven to 
be essential for tumour-induced NETosis [31].
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NETosis occurs in some infectious diseases as well as a number of non-infectious 
diseases. Some years ago, Hakkim and colleagues demonstrated that its incidence 
has increased in autoimmune diseases, such as lupus erythematodes [32]. Also, 
NETosis has recently been described to have a role in diabetes. It has been proven 
that hyperglycaemia is the cause of more frequent neutrophil activation and NET 
formation [33]. Additionally, it is assumed that NETs are included in the pathogen-
esis of some conditions, such as atherosclerosis [34].
The neutrophils and NETs released from them are important stimulators of 
thrombus formation processes in individuals with physiological and pathological 
conditions. Malignant diseases are risk factors for different types of thrombosis, 
and most often this is associated with the process of hypercoagulation as well as 
with increases in the capacity of activated neutrophils to form NETs. In the nine-
teenth century, Armand Trousseau reported the first data confirming the associa-
tion of cancer with thrombosis, later called Trousseau’s syndrome. The connection 
between NETs and thrombosis was demonstrated later, when Fuchs and colleagues 
showed that neutrophil extracellular traps provide a scaffold for activation of 
circulating platelets [35]. Since then, NETs have been considered to be involved 
in thrombosis processes related to cancer, and NETosis has been suggested to be 
a potential target for preventing thrombotic complications in malignant diseases 
[36]. Higher levels of NETs in blood stimulate the development of both arterial and 
venous thrombi.
Tumour-induced platelets have a critical role in the process of NETs’ release. 
Their immunomodulating effects are partially connected to their interactions 
with the inherent mediators of the immune system. The hyperactive condition of 
platelets in individuals with malignant diseases is due to the fact that many tumours 
express a tissue factor that leads to fibrin formation and platelet activation [37]. 
Their increased activation leads to the development of thrombosis and influences 
tumour genesis [38]. Therefore, it is generally accepted that neutrophils and plate-
lets are important regulators of tumour-induced NETosis.
It is established that the number of activated neutrophils and platelets increases 
in the presence of inflammatory and neoplastic diseases. The formation of com-
plexes between these cells is the main mechanism that connects haemostasis with 
inflammatory processes [39, 40]. About 50 years ago, the phenomenon of platelets 
adhering to neutrophils was described and termed ‘platelet satellitism’ [41]. These 
complexes are observed in a number of pathological conditions, such as bronchial 
asthma, chronic ulcerative colitis, sepsis, rheumatoid arthritis and acute coronary 
syndrome [42–45]. The first time these interactions were observed specifically in 
patients with cancer of the prostate gland was in 1975 [46]. The platelet–neutrophil 
complexes that were formed led to the mutual activation of platelets and neu-
trophils as well as the release of cytokines, exposition of adhesion molecules and 
receptors on the cell surface [39, 40]. This process of complex interaction is realised 
between the adhesion molecule P-selectin (CD62 P), which is located on the 
platelet surface, and the ligand P-selectin glycoprotein ligand-1 (PSGL-1), which 
is situated on neutrophils [47]. The important role of the interactions between 
integrated receptor molecules, such as glycoprotein 1b-IX-V and glycoprotein IIB/
IIa on the platelets and alpha-M-beta-2 on neutrophils, which initiate intracellular 
signal transduction [48–51], is emphasised. A number of studies demonstrated that 
activated neutrophils cause activation of platelets, similar to the way that activated 
platelets stimulate greater synthesis of NETs. Some interesting facts show that these 
circulating platelet–neutrophil complexes form the so-called ‘metastatic niche’ and 
accelerate the process of metastasis formation [52]. Tumour-induced NETosis is a 
promoter of subsequent pathological processes connected to the development and 
progression of cancer [53].
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Some prospective studies cite data confirming increased levels of circulating 
platelet–neutrophil complexes in patients with myeloproliferative diseases. The 
correlation of these complexes with the stage of the disease, the clinical course and 
treatment is of great interest. It has been found that patients with advanced stages 
of disease have higher levels of circulating complexes in their blood. In addition, 
the process of neutrophil activation, which is characterised by increased membrane 
expression of CD11b, release of proteolytic enzymes and platelet–neutrophil 
aggregates, contributes to the development of thrombosis [54].
Chemotherapy is related to an increased risk of developing thrombosis, but the 
pathogenetic mechanisms and the cytostatic agents that modulate haemostasis have 
not been fully clarified [55]. It is known that some of the cytostatics (e.g. doxoru-
bicin, epirubicin) used in therapy for malignant haemopathies and solid tumours 
induce tissue factor (TF) expression on the cancer cells, monocytes and the vascular 
smooth muscle fibres [56, 57]. Global coagulation assays are used to examine the 
effects of chemotherapeutic agents on the haemostatic balance, providing a good 
assessment of the pro- and anti-coagulant activity of these cells. Interestingly, treat-
ing patients with doxorubicin and epirubicin stimulates the expression of tissue 
factor and increases thrombin generation in defibrinated plasma. The procoagulant 
effect of anthracyclines on endothelial cells can cause an increase in the exposure of 
phosphatidylserine by caspase activation. Their effects on the activation of protein 
C have also been studied [58, 59]. To summarise, studies performed in vitro suggest 
that doxorubicin and epirubicin have the greatest prothrombotic potential to induce 
a procoagulant phenotype, as they provoke both apoptosis and NETosis.
In most publications, the preferred method to evaluate and assess the levels of 
circulating platelet–neutrophil complexes is flow cytometric analysis of venous 
blood after stimulation of the complexes with adenosine diphosphate and phorbol 
12-myristate 13-acetate. The conjugated antibody CD62 P (P-selectin) is used to 
assess the expression of CD11b and platelet–neutrophil complexes (CD41, CD45). 
Using this method, it has been established that the higher the percentage of circu-
lating complexes in blood, the higher the risk of thrombotic complications [60].
In conclusion, it should be emphasised that neutrophils and platelets are key 
regulators of tumour-induced NETosis. The neutrophils and formed NETs are 
important stimulators of the thrombotic processes. The identification of NETs 
and the characterisation of their role in disease have revived the overlooked role 
of neutrophils in disease pathogenesis. The analysis and evaluation of the levels of 
the circulating platelet–neutrophil complexes in blood in neoplastic diseases can be 
used as potential predictors of the occurrence of thrombosis. The flow cytometric 
method used for evaluation of the interaction between neutrophils and platelets 
achieves accurate and reproducible results.
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